Trulicity - supply shortage
Ongoing
dulaglutide
Shortage
Human
Shortage information
There is a shortage of Trulicity in some EU Member States.
Trulicity is a medicine used in addition to diet and exercise in adults and children from 10 years of age who have type 2 diabetes.
It is used on its own when use of metformin (another medicine for type 2 diabetes) is not recommended. It can also be used as an ‘add on’ to other diabetes medicines.
For further information on the use of the medicine please refer to the medicine’s overview page.
There has been an increase in demand for Trulicity, which has led to supply shortages. The shortages are expected to be resolved by the end of 2025.
The supply shortages are not related to a quality defect of the product or a safety issue.
Some EU Member States are currently affected or are at risk of being affected by the shortage.
For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- If Trulicity is unavailable, doctors should switch patients in time to a suitable alternative.
- For additional information, consult your country’s national shortage register or national competent authority.
- You may also contact relevant healthcare professional organisations for further information. A list of European not-for-profit organisations with which EMA engages can be found on the EMA website.
- If Trulicity is unavailable, your doctor will discuss the need to switch to a suitable alternative with you.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s national shortage register or national competent authority.
- You may also contact relevant patients’ organisations for further information or support. A list of European not-for-profit organisations with which EMA engages can be found on the EMA website.
Key facts
- Medicines affected
- Trulicity
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- dulaglutide
- Therapeutic area (MESH)
- Diabetes Mellitus, Type 2
- Pharmaceutical forms affected
- Solution for injection in pre-filled pen
- Strengths affected
- 0.75 mg
- 1.5 mg
- 3 mg
- 4.5 mg
- Availability of alternatives
- Yes
Key dates
- Expected resolution
- End of 2025
- First published
- Last updated